Previous studies have reported that the pCR rate of HER2-positive breast cancer patients receiving neoadjuvant therapy with taxane, carboplatin plus trastuzumab regimen ranges from 44%-64.9% (7, 9, 11, 12) for four courses and from 34.1%-57.5% (6, 8, 10, 13–21) for six courses. The gene discussed is ERBB2; the disease is breast cancer.